Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy

An N. Massaro, Yvonne W. Wu, Theo K. Bammler, Bryan Comstock, Amit Mathur, Robert C. McKinstry, Taeun Chang, Dennis E. Mayock, Sarah B. Mulkey, Krisa Van Meurs, Sandra Juul

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Objectives: To evaluate plasma brain specific proteins and cytokines as biomarkers of brain injury in newborns with hypoxic-ischemic encephalopathy (HIE) and, secondarily, to assess the effect of erythropoietin (Epo) treatment on the relationship between biomarkers and outcomes. Study design: A study of candidate brain injury biomarkers was conducted in the context of a phase II multicenter randomized trial evaluating Epo for neuroprotection in HIE. Plasma was collected at baseline (<24 hours) and on day 5. Brain injury was assessed by magnetic resonance imaging (MRI) and neurodevelopmental assessments at 1 year. The relationships between Epo, brain-specific proteins (S100B, ubiquitin carboxy-terminal hydrolase-L1 [UCH-L1], total Tau, neuron specific enolase), cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12P70, IL-13, interferon-gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], brain-derived neurotrophic factor [BDNF], monocyte chemoattractant protein-1), and brain injury were assessed. Results: In 50 newborns with encephalopathy, elevated baseline S100B, Tau, UCH-L1, IL-1β, IL-6, IL-8, IL-10, IL-13, TNF-α, and IFN-γ levels were associated with increasing brain injury severity by MRI. Higher baseline Tau and lower day 5 BDNF were associated with worse 1 year outcomes. No statistically significant evidence of Epo treatment modification on biomarkers was detected in this small cohort. Conclusions: Elevated plasma brain-specific proteins and cytokine levels in the first 24 hours of life are associated with worse brain injury by MRI in newborns with HIE. Only Tau and BDNF levels were found to be related to neurodevelopmental outcomes. The effect of Epo treatment on the relationships between biomarkers and brain injury in HIE requires further study. Trial registration: ClinicalTrials.gov: 01913340.

Original languageEnglish
Pages (from-to)67-75.e1
JournalJournal of Pediatrics
Volume194
DOIs
StatePublished - Mar 2018

Keywords

  • cytokine
  • erythropoietin
  • hypothermia
  • magnetic resonance imaging
  • neurodevelopment
  • tau protein
  • therapeutic

Fingerprint Dive into the research topics of 'Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy'. Together they form a unique fingerprint.

  • Cite this

    Massaro, A. N., Wu, Y. W., Bammler, T. K., Comstock, B., Mathur, A., McKinstry, R. C., Chang, T., Mayock, D. E., Mulkey, S. B., Van Meurs, K., & Juul, S. (2018). Plasma Biomarkers of Brain Injury in Neonatal Hypoxic-Ischemic Encephalopathy. Journal of Pediatrics, 194, 67-75.e1. https://doi.org/10.1016/j.jpeds.2017.10.060